Guildford's ANGLE strikes agreement with NuProbe USA
Guildford head-quartered liquid biopsy company ANGLE plc told investors it has inked an agreement with diagnostic group NuProbe USA Inc to use the latter's pan-cancer next generation sequencing (NGS) panel.
Under the deal, NuProbe has granted ANGLE, which has itself developed a cell harvesting technology called Parsortix, an option for an exclusive global license to the NGS panel outside China for the analysis of circulating tumor cells (CTCs) and the dual analysis of CTCs and circulating tumour DNA (ctDNA).
READ MORE: Biopharma firm ANGLE signs supplier deal with AstraZeneca
ANGLE said the agreement would help to accelerate its ability to commercialise its first pan-cancer molecular sequencing assay either for CTC-DNA analysis alone or dual analysis of CTCs and ctDNA from a single blood sample.
ANGLE's chief scientific officer Karen Miller said: "We are pleased to sign an agreement with NuProbe which will support our ongoing development of highly sensitive and specific molecular assays using CTCs harvested using the Parsortix system together with ctDNA from a single blood sample.
"Dual analysis of CTCs and ctDNA can provide additional and complementary information which will provide pharma services customers with unparalleled and repeatable insights into a range of cancers, and in the longer-term provide clinicians with the potential for continual optimisation of personalised cancer treatment plans."
The NGS panel enables highly sensitive and specific detection of over 6,500 DNA mutations in 61 clinically relevant genes and been found to be the highest performing multi-gene assay of those evaluated by ANGLE.
ANGLE said it has already successfully completed a pilot study with the NGS panel, with results published at the EACR annual meeting in June, 2024. See HERE.
NuProbe CEO Yingshuang Chai said: "By combining CTC and ctDNA detection, this collaboration will help drive the development of personalised treatment options for cancer patients.
"We look forward to the development of a strong partnership with ANGLE in the future."
